CHMP5 and breast carcinoma: In the analysis of antibody response among patients treated with different anticancer therapies, the breast cancer patients who had concurrent chemotherapy showed significantly lower antibody responses against SARS-CoV-2 Spike D614G protein than the non-cytotoxic treatment group but equivalent to the post-treatment group after the first vaccination (Figure 2C).